Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thyroid Cancer, Papillary 2 Polycystic Ovary Syndrome 2 Pituitary Neoplasms 2 Neoplasms 2 Diabetes Mellitus, Type 2 2 Adenocarcinoma, Follicular 2 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Cancers 1 Sezary Syndrome 1 Sarcoma 1 Prostatic Neoplasms 1 Pituitary ACTH Hypersecretion 1 Pancreatic Neoplasms 1 Obesity 1 Mycosis Fungoides 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Follicular 1 Liposarcoma 1 Leukoplakia, Oral 1 Head and Neck Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Alzheimer Disease 1 Adenocarcinoma Of Esophagus 1

Interventions

Doxorubicin 25 Radiotherapy 16 Ifosfamide 14 Trabectedin 10 pazopanib 6 ribociclib 5 pembrolizumab 5 Specimen Handling 5 Magnetic Resonance Spectroscopy 5 Gemcitabine 5 Biopsy 5 palbociclib 4 Radiation 4 Docetaxel 4 Chemotherapy, Adjuvant 4 selinexor 3 liposomal doxorubicin 3 eribulin 3 abemaciclib 3 X-Rays 3 Vincristine 3 Neoadjuvant Therapy 3 Imatinib Mesylate 3 Filgrastim 3 Etoposide 3 Cyclophosphamide 3 toripalimab 2 temsirolimus 2 romidepsin 2 pegfilgrastim 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Liposarcoma × Rosiglitazone × Clear all

NCT00004180 2023-06-26

Rosiglitazone in Treating Patients With Liposarcoma

Dana-Farber Cancer Institute

Phase 2 Completed

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡